NCT03813056View on ClinicalTrials.gov

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2025

Conditions
Fuchs Endothelial Dystrophy
Interventions
DRUG

Glanatec

Rho kinase Inhibitor

DRUG

Optive, Ophthalmic Solution

artificial tears (placebo)

PROCEDURE

Descemet Membrane Endothelial Keratoplasty

Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.

Trial Locations (1)

97210

RECRUITING

Devers Eye Institute, Portland

All Listed Sponsors
collaborator

Lions VisionGift Research

OTHER

collaborator

Eye Bank Association of America

OTHER

lead

Michael D. Straiko, MD

OTHER